CKDdb-logoCKDdb - Study ID Exp17081055

PubMed ID17081055
AuthorsNgai HH, Sit WH, Jiang PP, Xu RJ, Wan JM, Thongboonkerd V.
TitleSerial changes in urinary proteome profile of membranous nephropathy: implications for pathophysiology and biomarker discovery.
JournalJ Proteome Res. 2006 Nov;5(11):3038-47.
AbstractMembranous nephropathy is one of the most common causes of primary glomerular diseases worldwide. The present study adopted a gel-based proteomics approach to better understand the pathophysiology and define biomarker candidates of human membranous nephropathy using an animal model of passive Heymann nephritis (PHN). Clinical characteristics of Sprague-Dawley rats injected with rabbit anti-Fx1A antiserum mimicked those of human membranous nephropathy. Serial urine samples were collected at Days 0, 10, 20, 30, 40, and 50 after the injection with anti-Fx1A (number of rats = 6; total number of gels = 36). Urinary proteome profiles were examined using 2D-PAGE and SYPRO Ruby staining. Quantitative intensity analysis and ANOVA with Tukey post-hoc multiple comparisons revealed 37 differentially expressed proteins among 6 different time-points. These altered proteins were successfully identified by MALDI-TOF MS and classified into 6 categories: (i) proteins with decreased urinary excretion during PHN; (ii) proteins with increased urinary excretion during PHN; (iii) proteins with increased urinary excretion during PHN, but which finally returned to basal levels; (iv) proteins with increased urinary excretion during PHN, but which finally declined below basal levels; (v) proteins with undetectable levels in the urine during PHN; and (vi) proteins that were detectable in the urine only during PHN. Most of these altered proteins have functional significance in signaling pathways, glomerular trafficking, and controlling the glomerular permeability. The ones in categories (v) and (vi) may serve as biomarkers for detecting or monitoring membranous nephropathy. After normalization of the data with 24-h urine creatinine excretion, changes in 34 of initially 37 differentially expressed proteins remained statistically significant. These data underscore the significant impact of urinary proteomics in unraveling disease pathophysiology and biomarker discovery.

Sample characteristics

SpeciesTissue / SourceCompartmentDiseaseNDetection methodSample
Rattus norvegicusurinewholeGlomerulonephritis12MALDIDem17081055

Sample description and preparation

N (case)6
N (control)6
Disease (case)membranous nephropathy
Disease (control)healthy
Disease inductioni.v. inj. of 1 mL rabbit anti-Fx1A antiserum
Digestin-gel, trypsin
Separation2-DE

Molecule list

Molecule IDextExternal IDGeneNameSource accRegulation (case/control)Scores
A0216XSLMAP_RATSlmap, Slmap, Slmap_predictedSarcolemmal membrane-associated proteinGI:37360470regulation in disease: up
A0318XCADH1_RATCdh1Cadherin-1CADH1_RATregulation in disease: down
A0434 VEGFA_RATVegfa, Vegf, VegfaVascular endothelial growth factor AGI:32699992regulation in disease: up
A0850XVIME_RATVim, VimVimentinGI:38197662regulation in disease: down
A1222XRL5_RATRpl5, Rpl5l160S ribosomal protein L5GI:38014831regulation in disease: down
A149C MUP_RATLC11, LOC259246Major urinary proteinGI:204264regulation in disease: down
A1581XALBU_RATAlbSerum albumin ( Precursor)ALBU_RATregulation in disease: up
A1581XALBU_RATAlbSerum albumin ( Precursor)ALBU_RATregulation in disease: up
A1581XALBU_RATAlbSerum albumin ( Precursor)ALBU_RATregulation in disease: up
A1631XHPT_RATHpHaptoglobinGI:204657regulation in disease: up
A1631XHPT_RATHpHaptoglobinGI:33086640regulation in disease: up
A1631XHPT_RATHpHaptoglobinGI:33086640regulation in disease: up
A1631XHPT_RATHpHaptoglobinGI:33086640regulation in disease: up
A1631XHPT_RATHpHaptoglobinHPT_RATregulation in disease: up
A3205 TPM3_RATTpm3, Tpm-5, Tpm5Tropomyosin alpha-3 chainXP_355057regulation in disease: down
A3519 B5DFG538961, Nkrf, 38961Protein Sept6GI:26353410regulation in disease: down
A3585 AL1A1_RATAldh1a1, AldhRetinal dehydrogenase 1GI:32484332regulation in disease: down
A3667XGPDM_RATGpd2, Gpd2, Gpd2Glycerol-3-phosphate dehydrogenaseGPDM_MOUSEregulation in disease: up
A5222 TPM2_RATTpm2, Tpm2, MGC109519Tropomyosin beta chainTPM2_RATregulation in disease: down
A643CXTRFE_RATTf, Tf, SrprbSerotransferrinTRFE_RATregulation in disease: up
A643CXTRFE_RATTf, Tf, SrprbSerotransferrinTRFE_RATregulation in disease: up
A648CXTTHY_RATTtr, TtTransthyretinTTHY_RATregulation in disease: down
A6862 KLK7_RATKlk7, Klk-7, Klk7Glandular kallikrein-7NP_036725regulation in disease: down
A6862 KLK7_RATKlk7, Klk-7, Klk7Glandular kallikrein-7NP_036725regulation in disease: down
A7317 PCY1A_RATPcyt1a, Ctpct, Pcyt1Choline-phosphate cytidylyltransferase AGI:455294regulation in disease: up
A7422 PLCD1_RATPlcd1, Plcd11-phosphatidylinositol 4PLCD1_RATregulation in disease: up
A7671 REG3G_RATReg3g, Pap3Regenerating islet-derived protein 3-gammaGI:463280regulation in disease: down
A7671 REG3G_RATReg3g, Pap3Regenerating islet-derived protein 3-gammaGI:463280regulation in disease: down
XP_213585   XP_213585XP_213585regulation in disease: up
A8369XA1AT_RATSerpina1Alpha-1-antiproteinaseGI:203063regulation in disease: up
A8369XA1AT_RATSerpina1Alpha-1-antiproteinaseNP_071964regulation in disease: up
A8369XA1AT_RATSerpina1Alpha-1-antiproteinaseNP_071964regulation in disease: up
A8369XA1AT_RATSerpina1Alpha-1-antiproteinaseA1AT_RATregulation in disease: up
A8893 NAA35_RATNaa35, Egap, Emb8N-alpha-acetyltransferase 35GI:21539896regulation in disease: down
A8915 P2R3C_RATPpp2r3cSerine/threonine-protein phosphatase 2A regulatory subunit B'' subunit gammaGI:19354389regulation in disease: down
A8931 D3ZU21Pibf1, Pibf1, Pibf1Protein Pibf1NP_083596regulation in disease: down
A9729 MPP7_RATMpp7, Mpp7, Mpp7MAGUK p55 subfamily member 7GI:29437038regulation in disease: down

Compile date 08-10-2018© iMODE-CKD consortium